Company intelligence / Profile preview
AbbVie Inc.
- Ownership
- Public · ABBV
- Employees
- ~55000
- Development stage
- Commercial
Overview
AbbVie has a diverse portfolio of approved drugs and a robust pipeline across multiple therapeutic areas. Their blockbuster drug Humira has been highly successful in treating autoimmune diseases. The company has also developed treatments for cancer, including Venetoclax which has received multiple FDA approvals for different indications. Their pipeline includes drugs in various stages of development from discovery to approval.
- Therapeutic areas
- GastroenterologyPulmonologyOphthalmologyImmunologyDermatologyHematologyWomen's HealthOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesbiologics (including monoclonal antibodies)
- Industry
- Pharma
Drug pipeline
270 assets269 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on AbbVie Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbbVie Inc..